546.34MMarket Cap-1.39P/E (TTM)
8.600High7.780Low1.03MVolume8.340Open8.370Pre Close8.39MTurnover1.85%Turnover RatioLossP/E (Static)68.38MShares19.71052wk High-2.92P/B445.45MFloat Cap6.06552wk Low--Dividend TTM55.75MShs Float64.540Historical High--Div YieldTTM9.80%Amplitude5.840Historical Low8.127Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
No comment yet